ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 2093

Treatment of Advanced Knee OA with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial

Christopher Swearingen1, Yusuf Yazici2, Jeyanesh Tambiah3 and Philip G Conaghan4, 1Biosplice Therapeutics, Inc, San Diego, CA, 2NYU Grossman School of Medicine, La Jolla, CA, 3Biosplice Therapeutics Inc., San Diego, CA, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: clinical trial, Osteoarthritis, Patient reported outcomes, Response Criteria

Session Information

Date: Monday, November 18, 2024

Title: Osteoarthritis – Clinical Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Lorecivivint (LOR), an intra-articular CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways, demonstrated beneficial effects on clinical and radiographic outcomes in previous knee OA clinical trials. While clinical outcomes focus on differences between treatment groups, an individual’s “acceptable symptom state” may provide a meaningful and clinically relevant assessment. Year 1 results from a 2-year Phase 3 extension trial, OA-07 (NCT04520607), evaluating LOR 0.07 mg safety and efficacy with WOMAC Pain [0-100] and Function [0-100] subscales, are reported here within context of the Patient Acceptable Symptom State (PASS). The objective of this analysis was to evaluate long-term, repeated LOR treatment of severe knee OA patients as assessed by PASS.

Methods: Patients with structurally advanced knee OA (medial joint space width [JSW] 1.5-4.0 mm) who completed the parent Phase 3 trial (OA-11, NCT 03928184) were eligible for enrollment into OA-07. A repeat injection according to the original OA-11 trial randomization (LOR / placebo (PBO)) was given at the beginning of the OA-07 trial’s single-blind (for patients and investigators) phase. PASS was assessed annually at the start and the end of OA-07 Year 1, irrespective of symptom state, using a ‘yes/no’ response to the question “Taking into account all the activities you have during your daily life, your level of pain, and also your functional impairment, do you consider that your current state is satisfactory?” PASS response and odds ratios (OR; 95% CI) between treatment groups were calculated using baseline-adjusted logistic regression. Differences between treatment groups were explored for those patients with a positive PASS response.

Results: 276 patients (mean age 61.0 ± 8.2 years, BMI 31.8 ± 4.9 kg/m2, female 62.7%, KL3 45.3%, medial JSW 2.63 ± 0.69 mm, 67.4% bilaterally symptomatic, 68.5% medial JSW < 3 mm) were enrolled. LOR appeared safe and well-tolerated with no major adverse event rate differences compared to PBO during OA-07 Year 1. Treatment with LOR significantly increased the odds of reporting a ‘yes’ PASS response at the end of Year 1 (LOR 103 of 121 (85.1%) vs PBO 93 of 129 (71.1%), OR 2.45 [1.25, 4.78], P=0.009). Patients with a positive PASS response also reported greater improvement in WOMAC Pain (LOR -6.8 (± 2.0) vs PBO -1.0 (± 2.1), t-test P=0.049) and WOMAC Function (LOR -7.0 (± 1.9) vs PBO -2.4 (± 1.9), t-test P=0.090) at the end of Year 1 following the repeat injection at the start of the OA-07 extension study.

Conclusion: In this analysis of a phase 3 extension study of LOR compared to PBO, LOR-treated patients were significantly more likely to achieve a positive patient acceptable symptom state 12 months after a second injection. Pain and function outcomes showed greater improvement for those subjects reporting an acceptable symptom state. These data suggest that multiple once-yearly doses of LOR may provide long-term benefits for knee OA symptoms.

Supporting image 1

Figure 1: Patient Acceptable Symptom State between LOR and PBO at End of Year 1 Extension


Disclosures: C. Swearingen: Biosplice Therapeutics, Inc, 3; Y. Yazici: Amgen, 2, Biosplice, 8, Chugai, 2, Hemay, 2; J. Tambiah: Biosplice Therapeutics Inc, 3; P. Conaghan: AbbVie, 2, 6, Eupraxia Pharmaceuticals, 2, Galapagos, 2, Genascence, 2, Grünenthal, 2, GSK, 2, Janssen, 2, Levicept, 2, Lilly, 2, 6, Medipost, 2, Merck, 2, Moebius, 2, Novartis, 2, 6, Orion, 2, Pacira, 2, Sandoz, 6, Stryker, 2, Takeda, 2, TrialSpark, 2.

To cite this abstract in AMA style:

Swearingen C, Yazici Y, Tambiah J, Conaghan P. Treatment of Advanced Knee OA with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/treatment-of-advanced-knee-oa-with-lorecivivint-leads-to-improved-long-term-patient-acceptable-symptom-state-pass-compared-to-placebo-data-from-phase-3-extension-trial/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-of-advanced-knee-oa-with-lorecivivint-leads-to-improved-long-term-patient-acceptable-symptom-state-pass-compared-to-placebo-data-from-phase-3-extension-trial/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology